Celmatix and 23andMe Announce Launch of Fertility Research Community

Companies to recruit 4,500 women for ambitious Celmatix longitudinal
study to identify new markers related to reproductive health

NEW YORK–(BUSINESS WIRE)–Celmatix, a next-generation women’s health company, and 23andMe, the
leading personal genetics company, today announced the launch of a new
fertility research community. The goal of this initiative is to recruit
4,500 women, aged 18-45, who are trying to conceive or who have recently
conceived. In addition to collecting genetic data from participants, the
study will longitudinally track clinical, environmental, lifestyle,
diet-associated, and fertility outcome metrics. This dataset will
contribute to Celmatix’s larger research efforts, which are aimed at
understanding factors that contribute to lifelong reproductive potential
in a diverse population with the aim of identifying new genetic and
other markers related to reproductive health.

Women aged 18-45 who are trying to conceive or who have recently
conceived can participate from home by consenting to provide a DNA
sample (saliva), answering online surveys (one every two months for 18
months), and agreeing to share their de-identified, individual-level
data with researchers. All study participants will receive 23andMe’s
Personal Genome Service® at no cost. The study is currently open to U.S.
residents only.

Celmatix was founded with the goal of empowering women to be more
proactive in managing their reproductive health through better data,
including genetics,“ explained Celmatix founder and CEO, Dr. Piraye
Yurttas Beim. “23andMe is the ideal collaborator to help recruit and
manage this fertility research community given their shared vision for
enabling people to be more proactive about their health through genetic
insights and, also, the passion of their customer base for contributing
to groundbreaking research. This ambitious initiative will bring us
closer to enabling any woman, who may want to have a child one day,
better understand how decisions about lifestyle, diet, and when to start
building a family may impact her ability to have as many children as she
wants given her underlying genetics. Many studies have explored these
factors in isolation. This is the first study to bring them all together
in one longitudinal dataset.”

Many women struggle with fertility challenges, and yet there’s still a
limited understanding about what causes differences in fertility. For
women who have faced difficulties when trying to conceive, there is the
desire to understand why this is happening. And for women entering their
child-bearing years, it can be frustrating to realize there are
significant unknowns about one’s fertility that can have big
implications. Ultimately, this study has the capability to positively
impact our understanding of fertility by leveraging big data, helping
women understand their unique fertility, and empowering potential
parents to make informed choices,” explained Emily Drabant Conley, PhD,
vice president of business development from 23andMe.

Dr. Jorge E. Chavarro, MD, from the Harvard T.H. Chan School of Public
Health, and a scientific advisor to the study, stated, “The studies we
have available right now to counsel women on their reproductive
potential don’t include genetic-level insight and are generally smaller
and less detailed than studies in other areas of health. A landmark
study of this kind that simultaneously tracks the impact of environment,
diet, lifestyle, and clinical metrics in the context of genetic
background, on fertility potential and outcomes has never been conducted
on this scale. Not only does this work have the potential to drive the
next generation of personalized medicine products to impact clinical
management, but it will also likely result in significant contributions
to our fundamental understanding of the science of fertility.”

To learn more about the study, please visit www.23andme.com/fertility.

About Celmatix

Celmatix is a next-generation women’s health company transforming
reproductive health care through genomics and big data. Founded in 2009
and based in New York City, Celmatix is disrupting how women approach
their lifelong fertility journey by empowering them with more
personalized information. The company’s research-driven products include
Fertilome®, the world’s first multigene panel test that reveals what a
woman’s DNA says about her reproductive health, and Polaris®, a
real-time predictive analytics platform in use at leading fertility
clinics across the U.S., which helps physicians optimize patient
outcomes and improve the patient experience. For more information, visit www.celmatix.com.

About 23andMe

23andMe, Inc. is the leading personal genetics company. Founded in 2006,
the mission of the company is to help people access, understand and
benefit from the human genome. 23andMe has over one million customers
worldwide with over 80 percent consented to participate in research.
23andMe, Inc. is located in Mountain View, CA. More information is
available at www.23andMe.com.


for Celmatix
Rachel Petersen, 262-206-0627